Slide 1: Interventional Urology update
Interventional Urology update Coloplast Capital Markets Day 2018 Steffen Eichner Hovard, Senior Vice President, Interventional Urology
Slide 2: Interventional Urology is a global division that outpaces the market
Interventional Urology is a global division that outpaces the market with its comprehensive portfolio of solutions Interventional Urology at a Glance FY 16/17 >11% New name as Interventional Urology of Coloplast sales Endourology 1.6+ Men’s Health billion DKK annual sales Interventional Urology Wome
Slide 3: What is Interventional Urology
We provide solutions that substantially change patients’ urological conditions, a space called Interventional Urology What is Interventional Urology Patient treatment pathway Urological Conditions Adjust Interventional Urology Prescribe Manage Diet Intervene Rx regimen Chronic or temporary Implants,
Slide 4: The market continues to grow and witness increased price and regulatory pressures
The market continues to grow and witness increased price and regulatory pressures and new technology entrants Healthcare and Market Trends Patients Markets Customers Regulations Competitors • Aging global • Improved healthcare • Decision power shift • Heightened • New competitor population in develo
Slide 5: Interventional Urology is a DKK 12bn market growing 3-5% annually
Interventional Urology is a DKK 12bn market growing 3-5% annually Business Area Market Dynamics Market Size (DKKbn) Market growth ~4 • Portfolio breadth increasingly valued Endourology ~5% • Single-use visualization significant opportunity 4 ~3 • Penile implant market responding to patient awareness
Slide 6: We have successfully delivered on our strategy launched in 2014
We have successfully delivered on our strategy launched in 2014 and built a profitable, sustainable business Interventional Urology’s 2014 Ambition Core Drivers of Success Revenue, DKKbn Strong profitability Organizational 1 development DKK 2bn revenue 2.0 2 Operating as One 1.6 1.4 Globalizing our
Slide 7: Innovative products have contributed to our growth
Innovative products have contributed to our growth and laid the foundation for our portfolio strategy Innovation examples contributing to growth Resulting strategy around Innovation ReTrace® Access Sheath Titan® Touch inflatable Differentiated solutions to penile prostheses simplify procedures and i
Slide 8: Future value creation stems from efficiently delivered, differentiated solutions
Future value creation stems from efficiently delivered, differentiated solutions, and personal, trusted expertise Interventional Urology Priorities 1 2 3 4 PROVEN SOLUTIONS TRUSTED Proven Trusted Efficient Great EXPERTISE Solutions Expertise Operations Employees Expand and Provide our Transform Inve
Slide 9: Our continued growth is driven by investments in commercial expansion, innovation and adjacencies
Our continued growth is driven by investments in commercial expansion, innovation and new adjacencies Commercial growth drivers across in Urology Care Addressable market with innovation % Market Share, est. 16/17 Current market Market growth North America Europe Rest of World Potential Adjacencies •
Slide 10: By executing on our strategic priorities we will scale the business
By executing on our strategic priorities we will scale the business over time while sustaining strong profitability Scaling the Interventional Urology business organically Net Revenue, DKKbn 4.0 ~2.0 1.6 1.4 FY 14/15 FY 16/17 Near Future Future • . Page 10
Slide 11: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast Group - Ostomy Care /